Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Apyx Medical Corporation Common Stock

APYX

Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $2.44 – $2.68
Volume 15,459
Market cap $112M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$111.63M
Price / earnings
—
Price / book
11.59×
Price / sales
1.87×
EV / sales
2.04×
EV / EBITDA
-50.1×

Profitability

Earnings per share
-$0.20
Return on assets
-13.68%
Return on equity
-87.58%
Dividend yield
0%

Liquidity and leverage

Debt / equity
3.7×
Current ratio
4.95×
Quick ratio
3.85×
Cash ratio
2.37×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$8.89M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for APYX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$14.03M$13.88M$12.49M$19.16M$12.88M$11.37M$9.43M$14.22M
Cost of revenue$5.03M$5.01M$4.57M$7.17M$4.58M$4.29M$3.77M$5.26M
Gross profit$9M$8.87M$7.93M$12M$8.3M$7.08M$5.67M$8.96M
Selling, general and administrative$8.72M$9.88M$8.07M$11.04M$8.33M$8.83M$7.91M$10.9M
Research and development$849K$793K$765K$944K$801K$824K$804K$1.12M
Total operating expenses$9.56M$10.67M$8.8M$11.99M$9.05M$9.66M$8.72M$12.01M
Operating income-$562K-$1.8M-$875K$11K-$756K-$2.57M-$3.05M-$3.05M
Interest expense-$1.41M-$1.39M-$1.37M-$1.41M-$1.41M-$1.39M-$1.38M-$1.65M
Income before taxes-$1.69M-$2.95M-$2M-$1.15M-$1.88M-$3.69M-$4.12M-$4.57M
Income taxes$116K$124K$143K$94K$78K$49K$49K$89K
Net income-$1.81M-$3.07M-$2.14M-$1.24M-$1.96M-$3.74M-$4.17M-$4.66M
Net income attributable to common shareholders-$1.79M-$3.24M-$2.11M-$1.3M-$1.98M-$3.78M-$4.15M-$4.63M
EBITDA-$375K-$1.61M-$673K$232K-$592K-$2.44M-$2.91M-$2.91M
Basic earnings per share-$0.04-$0.07-$0.05-$0.03-$0.05-$0.09-$0.10-$0.12
Diluted earnings per share-$0.04-$0.07-$0.05-$0.03-$0.05-$0.09-$0.10-$0.12

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion®

Apyx Medical announced publication of clinical data demonstrating that a combination treatment approach using Avéli® for subcision and Renuvion® for plasma radiofrequency energy shows significant improvement in cellulite and skin laxity. In a study of 22 patients, 81.8% showed improvement in cellulite appearance at 180 days post-treatment, with objective imaging confirming measurable reductions in dimple volume and histological evidence of increased collagen and elastin.

GlobeNewswire Inc.

Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™

Apyx Medical received FDA 510(k) clearance to add power liposuction capability to its AYON Body Contouring System, an advanced liposuction modality using reciprocating cannulas to improve surgical efficiency. The company plans a limited commercial launch to work with early adopters before broader scaling. This expansion positions AYON as a comprehensive all-in-one platform combining fat removal, tissue contouring, and electrosurgical capabilities.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.